期刊文献+

葡甲胺环腺苷酸对充血性心力衰竭患者心功能的影响 被引量:4

Effect of meglumini cyclo-adenylate on cardiac function in patients with congestive heart failure
原文传递
导出
摘要 目的 观察葡甲胺环腺苷酸 (MCA)对心力衰竭患者 (CHF)心功能的影响 ,探讨其作用机理。方法 CHF患者 12例 ,心功能Ⅲ~Ⅳ级 ,给予MCA 90mg稀释后静点 ,用漂浮导管监测给药前及给药后 3h的心功能参数变化。结果 MCA降低肺动脉平均压 [(39.0 0± 12 .2 4)vs (35 .17± 10 .6 9)mmHg]和肺动脉镶嵌压 [(2 5 .17± 7.76 )vs (2 1.0 8± 6 .82 )mmHg] ,增加心指数 [(2 .6 5± 0 .6 6 )vs (2 .81± 0 .5 2 )L/m /m2 ]和心搏量 [(4.6 3± 1.33)vs (4.92± 1.39)L/m] ,并减少体循环阻力 [(2 14 1.5 8± 792 .5 1)vs (180 7.83± 5 84.2 1)dyness·s·cm 5]和肺循环阻力 [(75 0 .2 7± 36 8.12 )vs (6 0 1.0 0± 5 84.2 1)dyness·s·cm 5] ,使右房压降低 [(11.17± 3 .91)vs (9.33± 3 .5 5 )mmHg]。 结论 MCA可以改善心功能 ,降低循环阻力和后负荷。 Objective To evaluate the effects of meglumini cyclo adenylate(MCA) on cardiac function in patients with congestive heart failure(CHF).Methods The cardiac catheterization was performed in 12 patients with CHF, and the parameters of heart function were investigated before and after intravenous 90 mg MCA drip.Results After intravenous MCA drip, the mean pressure of pulmonary artery,diastolic pressure of pulmonary artery, resistance of systematic circulation, resistance pulmonary circulation and pressure of right atrium decresed. The cardiac index and output increased.Conclusion MCA improves cardiac function by reduction of circulative resistance and afterload, hence it is a useful agent for CHF.
出处 《临床内科杂志》 CAS 北大核心 2001年第1期24-25,共2页 Journal of Clinical Internal Medicine
关键词 环磷酸腺苷 药物疗法 充血性心力衰竭 治疗 心功能 Meglumini cyclo adenylate Heart failure/drug therapy
  • 相关文献

参考文献8

  • 1[1]Grossman JD,Bishop A.Deficient cellular cyclic AMP may cause both cardiac and skeletal muscle dysfunction in heart failure.J Card Fail,1996,2(4 Suppl)∶S105-111.
  • 2[2]Gao M,Ping P.Increased expression of adenylycyclase type Ⅵ proportionely cAMP in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA,1998,95(3)∶1038-1043.
  • 3[3]Money-Kyrle AR,Davies CH,Ranu HK,et al.The role of cAMP in the frequency-dependent changes in contraction of guinea-pig cardiomyocytes.Cardiovasc Res,1998,37(2)∶532-540.
  • 4[4]Schmidt U,Hajjar RJ,Kim CS,Lebeche D.Human heart failure: cAMP stimulation of Ca2+-ATPase activity and phosphorylation level of phospholamban. Am J Physiol,1999,277(2pt2)∶H474-480.
  • 5[5]Kirchhefer U,Schmitz W,Scholz H,et al.Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human.Cardiovasc Res,1999,42(1)∶254-261.
  • 6[6]Mulieri LA,Leavitt BJ,Wright RK.Role of cAMP in modulation kinetics and the fouce-frequency relation in mitral regurgitation heart failure.Basic Res Cardiol,1997,92∶95-103.
  • 7[7]Nakanishi M,Yokota Y,Fukuzaki H.Cardiovascular effects of dibutyryl cyclic AMP in patients with congestive heart failure-comparison with dobutamine and captopril.Jpn Circ J,1988,52(6)∶503-510.
  • 8[8]Hoshino Y.Cute effects of dibutyryl cyclic AMP on renal circulation in congestive heart failure.Jpn Heart J,1988,29(6)∶711-719.

同被引文献9

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部